durvalumab,tremelimumab
astrazeneca,pfizer
['poseidon', 'durva', 'tremelimumab']
update on poseidon shows a sustained survival benefit of durvalumab + tremelimumab + chemo vs chemo alone (os hr 0.75) with a 3y os rate of 25% and benefit seen in pdl1 low or negative. durva + chemo os hr 0.84 vs chemo alone. #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him